The combination of a fibric acid derivative (fibrate) and a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) may offer a therapeutic advantage to patients with combined hyperlipidemia who respond inadequately to either agent alone. However, physicians remain reluctant to prescribe statins and fibrates concomitantly because of their concern that drug-drug interactions will increase the probability of muscle damage. Fibrates have been shown to increase statin plasma concentrations and to be associated with an increased risk of severe myopathy and rhabdomyolysis when prescribed in combination with a statin.1,2 The question of whether the increase in risk is due to a class effect for all fibrate-statin combinations remains unanswered.
Ballantyne CM, Davidson MH. Possible Differences Between Fibrates in Pharmacokinetic Interactions With Statins. Arch Intern Med. 2003;163(19):2394–2395. doi:10.1001/archinte.163.19.2394
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.